UBS Group’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

UBS Group’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-87,639	Closed	-$585K	–	10306
2023 Q3	$585K	Buy	87,639 +24,463	+39%	+$203K	﹤0.01%	4535
2023 Q2	$572K	Buy	63,176 +29,894	+90%	+$264K	﹤0.01%	4707
2023 Q1	$242K	Sell	33,282 -67,475	-67%	-$501K	﹤0.01%	5246
2022 Q4	$735K	Buy	100,757 +74,704	+287%	+$554K	﹤0.01%	4354
2022 Q3	$201K	Buy	26,053 +14,719	+130%	+$125K	﹤0.01%	5075
2022 Q2	$77K	Buy	+11,334	New	+$86.7K	﹤0.01%	5616
2022 Q1	–	Sell	-2,455	Closed	-$14K	–	11186
2021 Q4	$14K	Buy	+2,455	New	+$18.4K	﹤0.01%	8380
2021 Q3	–	Sell	-509	Closed	-$5K	–	10304
2021 Q2	$5K	Sell	509 -4,016	-89%	-$40.8K	﹤0.01%	8593
2021 Q1	$48K	Buy	4,525 +3,577	+377%	+$48.5K	﹤0.01%	6603
2020 Q4	$13K	Buy	+948	New	+$13.2K	﹤0.01%	7299

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

UBS Group's PNT Position: Q4 2023 in Review

UBS Group sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 87,639 shares — an estimated $585K sold.

UBS Group first reported a position in PNT in Q4 2020 and held it in 10 quarters. The position peaked at $735K in Q4 2022. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

UBS Group reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
UBS Group sold 87,639 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $585K.
UBS Group first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2020 and held it in 10 quarters.
UBS Group's POINT Biopharma Global Inc. Common Stock position peaked at $735K in Q4 2022.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.